Skip to main content
GENEMATRIX INC. logo

GENEMATRIX INC. — Investor Relations & Filings

Ticker · 109820 ISIN · KR7109820001 KO Manufacturing
Filings indexed 175 across all filing types
Latest filing 2024-08-20 Regulatory Filings
Country KR South Korea
Listing KO 109820

About GENEMATRIX INC.

https://genematrix.net/en

GENEMATRIX INC. is a biotechnology company that develops molecular diagnostic products and promotes new drug development. The company specializes in multiplex real-time PCR technology, which enables the simultaneous detection of multiple pathogens in a single test. Its core product line, NeoPlex™, offers a range of diagnostic assays for infectious diseases, including comprehensive panels for respiratory viruses and bacteria, human papillomavirus (HPV), and tuberculosis. GENEMATRIX focuses on creating innovative platform technologies to advance diagnostics and is also expanding into AI-powered solutions for precision medicine.

Recent filings

Filing Released Lang Actions
조회공시요구(현저한시황변동)에대한답변(중요정보없음)
Regulatory Filings Classification · 100% confidence The document is a formal response to a Korea Exchange (KRX) inquiry regarding significant market fluctuations (unusual stock price/volume activity). It explicitly states that the company has no material non-public information to disclose. As this is a standard regulatory response to a market inquiry and does not fit into specific categories like financial reports or corporate actions, it falls under the general regulatory filing category.
2024-08-20 Korean
조회공시요구(현저한시황변동)
Regulatory Filings Classification · 100% confidence The document is a formal request from a regulatory body (exchange) to the company (GeneMatrix) regarding significant market fluctuations in its stock price. This is a standard regulatory inquiry/announcement regarding market activity, which does not fit into specific financial reporting categories like 10-K or IR, and is best classified as a general regulatory filing.
2024-08-19 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Genematrix' (진매트릭스) covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business operations, and management discussions, which is characteristic of an interim/quarterly report. It is not an announcement of a report, but the report itself. H1 2024
2024-08-14 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Genematrix' (진매트릭스) covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides the official outcomes of the shareholder votes held on 2024-03-28, including the approval of financial statements and director/auditor compensation. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2024-03-28 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and auditor information for the fiscal year. While it contains financial data, it is a formal notification of the audit report's submission rather than the full annual report (10-K) or a standalone audit report (AR). According to the 'Menu vs Meal' rule, this is a notification of the report's availability, making it a Report Publication Announcement (RPA). FY 2023
2024-03-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.